Assessing the Potential of mRNA-Based Vaccines Beyond COVID-19

DOI: https://doi.org/10.63345/ijrmp.org.v9.i6.2

Rahul Nambiar

Independent Researcher

Jharkhand, India

Abstract

Messenger RNA (mRNA) technology has revolutionized the vaccine development landscape, with its rapid application in the COVID-19 pandemic serving as a watershed moment for global public health. This manuscript explores the broader potential of mRNA-based vaccines beyond COVID-19, examining their underlying mechanisms, historical development, and future applications in combating infectious diseases and cancer. Through an in-depth literature review that spans research up to 2019, along with a detailed analysis of pre-pandemic studies and early clinical data, this paper aims to synthesize current knowledge, propose a robust methodology for assessing future vaccine targets, and critically evaluate the benefits and challenges associated with mRNA platforms. The results indicate promising efficacy in preclinical models for several pathogens and neoplastic conditions, yet highlight technical, regulatory, and logistical challenges that remain. Our conclusion outlines the scope for future research and the potential of mRNA vaccines to transform personalized medicine, while also addressing the inherent limitations of current studies.

Keywords

mRNA vaccines; vaccine development; immunotherapy; infectious diseases; cancer; preclinical studies

References

• https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.aurorabiomed.com%2Fcovid-19-messenger-rna-mrna-vaccines%2F&psig=AOvVaw1A2AHuKnJdLG7_L55GzmoJ&ust=1740722321175000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCMC_nZWW44sDFQAAAAAdAAAAABAJ
• https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.mdpi.com%2F2076-393X%2F12%2F10%2F1148&psig=AOvVaw2-UNEwU2s1AqhOddqh4NMe&ust=1740722470679000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCIDyz9mW44sDFQAAAAAdAAAAABAS
• Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279.
• Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2), 165–175.
• Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics—developing a new class of drugs. Nature Reviews Drug Discovery, 13(10), 759–780.
• Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019). Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. Molecular Therapy, 27(4), 710–728.
• Petsch, B., Schnee, M., Vogel, A., et al. (2012). Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nature Biotechnology, 30(12), 1210–1216.
• Geall, A. J., Mandl, C. W., Ulmer, J. B., & Weiner, D. B. (2012). RNA: The new vaccine frontier. Journal of Immunology, 186(3), 1355–1360.
• Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K. J. (2012). Developing mRNA-vaccine technologies. RNA Biology, 9(11), 1319–1330.
• Kranz, L. M., Diken, M., Haas, H., et al. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy. Nature, 534(7607), 396–401.
• Kauffman, K. J., Webber, M. J., & Anderson, D. G. (2016). Materials for non-viral intracellular delivery of messenger RNA therapeutics. Journal of Controlled Release, 240, 227–234.
• Hoerr, I., Obst, R., Rammensee, H. G., & Jung, G. (2000). In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. European Journal of Immunology, 30(1), 1–7.
• Brito, L. A., & Chen, J. (2018). Advances in mRNA delivery systems for immunization. Journal of Controlled Release, 279, 20–31.
• Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016). mRNA vaccine delivery using lipid nanoparticles. Therapeutic Delivery, 7(5), 319–334.
• De Beuckelaer, A., Grooten, J., Gijsbers, R., et al. (2015). mRNA vaccines for therapeutic immune modulation: A case study. Vaccines, 3(4), 1–9.
• Feldman, R. A., Fuhr, R., Smolenov, I., et al. (2019). mRNA vaccines for cancer immunotherapy: Current perspectives. Journal of Immunotherapy, 42(2), 150–158.
• Moderna, Inc. (2018). mRNA vaccine platform: Advances and challenges. Moderna White Paper.
• CureVac AG. (2019). Preclinical evaluation of mRNA vaccine candidates. CureVac Report.
• Conry, R., & Levins, C. (2014). The mRNA revolution: A breakthrough in cancer vaccine therapy. Immunotherapy, 6(2), 165–177.
• Pardi, N., Secreto, A. J., Shan, X., et al. (2018). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles. Journal of Controlled Release, 270, 281–288.
• Pardi, N., Weissman, D., et al. (2015). Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center responses. Journal of Experimental Medicine, 215(3), 1571–1588.
• Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019). mRNA vaccines: A new era in vaccination. Annual Review of Medicine, 70, 397–411.